依据《上海证券交易所非公开发行公司债券挂牌规则》等规定，上交所同意郑州高新产业投资集团有限 公司2025年面向专业投资者非公开发行科技创新公司债券（第一期）于2025年12月8日起在上交所挂 牌，并采取点击成交、询价成交、竞买成交、协商成交交易方式。该债券证券简称为"25郑产K1"，证 券代码为"280880"。 12月5日，上交所发布关于郑州高新产业投资集团有限公司2025年面向专业投资者非公开发行科技创新 公司债券（第一期）挂牌的公告。 来源：市场资讯 ...

□ 本报记者陈月飞 江苏新业态、新赛道多，有条件、有基础的地区不断在创制性、探索性立法上下功夫，发挥立法对新产 业（300832）、新业态、新模式的引领保障作用。无锡是全国首批获得地方立法权的13个较大的市之 一，1986年获得地方立法权以来，累计制定地方性法规114件，其中5件开创全国同类地方立法先河。 总结这些年来的立法经验，无锡市人大常委会副主任、党组副书记曹佳中表示，其中一条就是聚力推进 新质生产力领域立法。"我们先后制定科技创新促进条例、车联网发展促进条例、数字化转型促进条 例、数据条例、低空经济发展促进条例，正在制定知识产权促进和保护条例，下一步，还将制定人工智 能产业促进条例，为发展新质生产力注入法治动能。" 江苏是改革开放前沿阵地，对于国家尚未立法，而我省已形成改革发展经验的领域，江苏注重用好用足 地方立法权限，为国家和省级立法积累经验。2015年以来，省人大常委会共完成创制性立法78部，其中 首创性立法20部。 去年11月施行的《江苏省生产经营单位安全风险管理条例》，是全国首次以安全风险管理为主要内容的 地方性立法。省应急管理厅厅长、党委书记任栋表示，条例实施以来，生产经营单位通过风险报告系 ...

此外，三友集团还不断以产品创新占领高端市场，对接5G、航空航天等新兴市场需求，开发了硅基、 镁基、溴系列、氯系列等高附加值、高技术含量、高市场占有率产品40余个，可持续粘胶短纤维等15项 技术产品达到国际国内先进水平，新产品产值占比达30%以上，高端产品产值占比达45%以上。 编辑：胡晨曦 新华财经石家庄12月4日电（记者刘桃熊）记者从唐山三友集团了解到，当前三友集团正在实施向海洋 转身、向绿色转型、向高质量转变"三转"战略，确定了由传统化工企业向高科技企业转型的发展目标， 2022年以来累计研发投入近40亿元，研发投入强度达5.7%。 "近年来三友集团实施了高端电子化学品等3个百亿项目，成立了蓝海科技等6家新公司，预计整体投产 后，战新产业占比达70%以上。"三友集团总经理李建渊介绍，其中，高端电子化学品项目可解决进 口"卡脖子"问题，实现国产化替代；钠电池项目方面，先后建成了国内首条规模化电池级碳酸钠生产线 和全球首套应用于工业领域的钠电储能设备；浓海水资源综合利用项目方面，国际首创了浓海水高效利 用技术，解决了海水淡化后排废浓海水处理的世界难题。 转自：新华财经 ...

Core Points - The Medical Health R Index (480016) closed at 7284.72 points, down 0.42%, with a trading volume of 17.046 billion yuan and a turnover rate of 0.61% [1] - Among the index constituents, 23 stocks rose while 26 fell, with TeBao Bio leading the gainers at 2.85% and Renfu Pharmaceutical leading the decliners at 3.33% [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.66%, latest price at 87.62, down 2.01%, and a market cap of 261.437 billion yuan [1] - Hengrui Medicine (sh600276) with a weight of 11.00%, latest price at 60.97, down 0.25%, and a market cap of 404.670 billion yuan [1] - Mindray Medical (sz300760) with a weight of 7.57%, latest price at 199.50, down 0.56%, and a market cap of 241.882 billion yuan [1] - United Imaging Healthcare (sh688271) with a weight of 4.27%, latest price at 128.88, up 0.13%, and a market cap of 106.217 billion yuan [1] - Pianzai Shou (sh600436) with a weight of 3.48%, latest price at 171.48, up 1.33%, and a market cap of 103.457 billion yuan [1] - Aier Eye Hospital (sz300015) with a weight of 3.42%, latest price at 11.35, down 1.30%, and a market cap of 105.843 billion yuan [1] - Kelun Pharmaceutical (sz002422) with a weight of 2.59%, latest price at 34.00, down 0.03%, and a market cap of 54.334 billion yuan [1] - Xinhecheng (sz002001) with a weight of 2.42%, latest price at 24.44, up 0.20%, and a market cap of 75.114 billion yuan [1] - Fosun Pharma (sh600196) with a weight of 2.39%, latest price at 27.05, down 0.15%, and a market cap of 72.235 billion yuan [1] - Ziji Shenzhou (sh688235) with a weight of 2.27%, latest price at 275.20, down 1.59%, and a market cap of 423.995 billion yuan [1] Capital Flow Analysis - The Medical Health R Index constituents experienced a net outflow of 1.159 billion yuan from institutional investors, while retail investors saw a net inflow of 999 million yuan [1] - Detailed capital flow for specific stocks shows: - Health元 (600380) had a net inflow of 34.2431 million yuan from institutional investors [2] - Hengrui Medicine (600276) had a net inflow of 29.9909 million yuan from institutional investors [2] - Long Spring High-tech (000661) had a net inflow of 19.8154 million yuan from institutional investors [2] - The index constituents underwent adjustments, adding four new stocks and removing one [2]

苏州高新（600736）(600736.SH)发布公告，2025年12月3日，公司全资孙公司苏州高新产业（300832） 新城建设发展有限公司通过市场竞拍方式取得江苏省苏州市苏地2025-WG-Z30号宗地土地使用权，成交 价3.6亿元。 ...

Core Viewpoint - The report from Huachuang Securities indicates that the company's domestic business testing volume has grown against the trend, while overseas business has experienced rapid growth, and gross profit margins continue to improve [1] Domestic Market Performance - In the domestic market, the company achieved a main business revenue of 1.955 billion yuan in Q1-Q3 of 2025, a year-on-year decrease of 11%, primarily due to the impact of centralized procurement and the unbundling of testing packages [1] - Despite the overall pressure on testing volumes in the industry, the company has increased its market share, resulting in a counter-trend growth in testing volume, demonstrating strong business resilience [1] Overseas Market Performance - In the overseas market, the company achieved a main business revenue of 1.467 billion yuan in Q1-Q3 of 2025, a year-on-year increase of 21%, with the reagent business performing particularly well, showing a revenue growth of 37% [1] - The overseas comprehensive gross profit margin increased to 69.49%, surpassing the domestic market level, indicating clear support for the ongoing improvement in overseas gross margins [1] Future Outlook - The rapid expansion of production lines signifies a substantial breakthrough in the company's market expansion within large domestic medical terminals, which is expected to gradually drive steady growth in conventional reagent sales [1] - Based on the DCF model, the overall valuation of the company is estimated at 61.2 billion yuan, corresponding to a target price of approximately 78 yuan, maintaining a "recommend" rating [1]

南财投研通数据显示，12月2日，券商给予上市公司目标价共7次，按最新收盘价计算，目标价涨幅排名居前的公司有先惠技术、贵州茅台、 德尔股份，目标价涨幅分别为42.61%、42.06%、36.94%，分别属于电池、白酒、汽车零部件行业。 | | | 12月02日目标价涨幅排名 | | | | | --- | --- | --- | --- | --- | --- | | 证券代码 | 证券名称 | 机构 | 最新评级 | 最高目标价 | 目标涨幅 | | | | | | (元) | (%) | | 688155 | 先惠技术 | 中信证券 | 买人 | 84.00 | 42.61 | | 600519 | 贵州茅台 | 国泰海通证券 | 增持 | 2040.00 | 42.06 | | 300473 | 德尔股份 | 东北证券 | 买人 | 38.59 | 36.94 | | 301360 | 荣旗科技 | 东北证券 | 买人 | 96.11 | 35.39 | | 300832 | 新产业 | 华创证券 | 推荐 | 78.00 | 32.09 | | 688179 | 阿拉丁 | 中信证券 | 买人 | 17 ...

Investment Rating - The report maintains a "Recommendation" rating for the company with a target price of 78 yuan [2][8]. Core Insights - The company reported a revenue of 3.428 billion yuan for the first three quarters of 2025, reflecting a slight increase of 0.39% year-on-year, while the net profit attributable to the parent company decreased by 12.92% to 1.205 billion yuan [2]. - The overseas business is experiencing rapid growth, with a 21% year-on-year increase in revenue, particularly in the reagent business, which saw a 37% increase [8]. - The company is optimizing its installation structure, with 1,144 automated chemical luminescence instruments installed in the domestic market, 78% of which are large machines, indicating a significant improvement compared to the same period in 2024 [8]. Financial Performance Summary - For 2025, the company expects total revenue to reach 4.787 billion yuan, with a year-on-year growth rate of 5.6% [4]. - The net profit attributable to the parent company is projected to be 1.786 billion yuan, reflecting a slight decline of 2.3% [4]. - The earnings per share (EPS) for 2025 is estimated at 2.27 yuan, with a price-to-earnings (P/E) ratio of 26 [4]. Market Dynamics - The domestic market is facing challenges, with a 11% decline in main business revenue to 1.955 billion yuan due to factors like centralized procurement and unbundling of testing packages [8]. - The overseas market is less affected by policy uncertainties, and the gross margin for overseas operations has improved to 69.49%, surpassing domestic levels [8]. - The company is transitioning to higher-margin X-series products, which is expected to support long-term growth [8].

Core Insights - Tianjin Tuanbo Huahai Haihe Innovation Industry Development Equity Investment Fund Partnership (Limited Partnership) has been established with a capital contribution of 500 million RMB [1][2][3] - The fund's primary activities include private equity investment, investment management, and asset management [1][2] - The executing partner is Tianjin Haitang Venture Capital Management Center (Limited Partnership) [1][2] Group 1 - The fund is a collaboration among several partners, including Tianjin Huahai Investment Management Co., Ltd., Tianjin Haihe Industrial Fund Partnership (Limited Partnership), and Tianjin Renai Bo Heng Enterprise Management Co., Ltd. [1][2][3] - The fund is registered under the Tianjin Jinghai District Market Supervision Administration [2] - The business scope requires registration and filing with the Asset Management Association of China [1][2]

天眼查App显示，近日，天津团泊华海海河创新产业发展股权投资基金合伙企业（有限合伙）成立，执 行事务合伙人为天津海棠创业投资管理中心（有限合伙），出资额5亿人民币，经营范围为以私募基金 从事股权投资、投资管理、资产管理等活动。合伙人信息显示，该基金由天津华海投资管理有限公司、 天津市海河产业基金合伙企业（有限合伙）、天津仁爱博恒企业管理有限公司等共同出资。 ...